Earnings Calls

Last Earnings Call

Fiscal Period
Q2 2026
Call Date
Aug 12, 2026
AI Summary
Q2 2026

Outlook raised: Demant lifted 2026 organic revenue growth guidance to 6% to 7% and EBIT before special items to DKK 4.4 billion to DKK 4.8 billion after a strong first half and better second-half momentum.

Strong first half: Reported revenue rose 15%, with 7% organic growth and 10% acquisitive growth, led by Hearing Aids, Hearing Care, and Diagnostics.

Margins improved: Gross margin increased by 1.1 percentage points, helped by stronger product and geography mix in Hearing Aids and the KIND acquisition in Hearing Care.

Launch momentum: Oticon Zeal continued to drive strong growth, and Demant said the newly announced Oticon Reveal should further support growth and pricing.

Costs and cash: Cost-saving initiatives are progressing ahead of plan, cash flow was strong, and leverage has already fallen to 3.0, ahead of the company’s deleveraging plan.

Key Financials
Revenue
15%
Organic revenue growth
7%
Acquisitive growth
10%
FX effect on revenue
-3%
Gross margin
1.1 percentage points
Gross profit
just shy of DKK 10 billion
OpEx growth
5%
EBIT before special items
DKK 2.134 billion
EBIT margin
16.5%
Cash flow from operations
DKK 1.6 billion
Net cash inflow from acquisitions and divestments
DKK 91 million
Net debt / gearing
3.0
Special items
DKK 216 million
KIND integration special items
DKK 150 million
Cost-saving initiative special items
DKK 250 million
Cost effectiveness program contribution
DKK 300 million
KIND EBIT contribution
DKK 325 million
Tariff refund
DKK 25 million
Hearing aid market growth
4% in value, 3% in units
Hearing Aids growth in Q2
10%
Hearing Care growth in Q2
31%
Diagnostics growth in Q2
9%
Earnings Call Recording

Other Earnings Calls